Real life experiences in HCV management in 2018

M. Viganò, M. Andreoni, C.F. Perno, A. Craxì, A. Aghemo, A. Alberti, P. Andreone, S. Babudieri, S. Bonora, M.R. Brunetto, R. Bruno, S. Bruno, V. Calvaruso, N. Caporaso, F. Cartabellotta, F. Ceccherini-Silberstein, V. Cento, A. Ciancio, P. Colombatto, N. CoppolaV. Di Marco, G. Di Perri, S. Fagiuoli, G.B. Gaeta, A. Gasbarrini, P. Lampertico, A. Pellicelli, T. Prestileo, M. Puoti, G. Raimondo, G. Rizzardini, G. Taliani, A.L. Zignego

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)117-128
Number of pages12
JournalExpert Review of Anti-Infective Therapy
Volume17
Issue number2
DOIs
Publication statusPublished - 2019

Keywords

  • Antiviral therapy
  • chronic liver disease
  • DAAs
  • HCV
  • hepatitis C virus
  • antivirus agent
  • glecaprevir plus pibrentasvir
  • nonstructural protein 5A inhibitor
  • pibrentasvir
  • sofosbuvir
  • sofosbuvir plus velpatasvir plus voxilaprevir
  • velpatasvir
  • antiviral resistance
  • antiviral susceptibility
  • antiviral therapy
  • decompensated liver cirrhosis
  • disease burden
  • drug efficacy
  • drug response
  • drug safety
  • health care access
  • hepatitis B
  • Hepatitis B virus
  • hepatitis C
  • Hepatitis C virus
  • human
  • Human immunodeficiency virus infection
  • Italy
  • kidney failure
  • liver cell carcinoma
  • liver fibrosis
  • mixed infection
  • nonhuman
  • practice guideline
  • Review
  • viral clearance

Cite this